Posaconazole, an orally available extended-spectrum triazole antifungal, has been shown to be effective for prophylaxis in immunocompromised patients who are at high risk for invasive fungal infection (IFI) (2, 12) and as a treatment for many important fungal pathogens, including Aspergillus, Candida, Cryptococcus, and Fusarium species and the zygomycetes (2, 6, 9, 12, 14) .
Several studies have demonstrated that the bioavailability of posaconazole is significantly enhanced when the drug is given with food (3) (posaconazole [Noxafil] oral suspension package insert; Schering-Plough, Kenilworth, NJ), presumably because of an increase in dissolution. Because patients at risk for IFI are often critically ill and may be unable to eat, do not want to eat, or are not allowed to eat due to mucositis, severe nausea, or pancreatitis (7, 10) , liquid nutritional supplements are often administered, either orally or via an enteral feeding tube, to this patient population.
A previous study reported that posaconazole bioavailability is significantly increased when the drug is given with 8 fluid ounces (oz) of a nutritional supplement (Boost Plus) (10) . The aim of this study was to investigate the effects of varying amounts of nutritional supplement on posaconazole bioavailability, to determine whether an amount less than 8 oz would also be effective in enhancing bioavailability.
(These data were presented in part at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, 25 to 28 October 2008.)
MATERIALS AND METHODS

Study design.
This was a single-center, phase 1, randomized, 5 by 5 crossover, open-label study conducted in accordance with good clinical practice.
The study consisted of five treatment periods and five treatment groups (Table  1) . Subjects (n ϭ 30) were randomized to receive all five treatments at a 1:1:1:1:1 ratio in one of five treatment sequences (six subjects per sequence) ( Table 2) . In each period, after an overnight fast, subjects were administered a single dose of 400 mg posaconazole as a 10-ml oral suspension either alone or 5 to 10 min after consumption of Boost Plus nutritional supplement in varying amounts (8 , were screened up to 30 days before study initiation. Baseline clinical laboratory tests, electrocardiograms (ECGs), and vital sign measurements had to be within normal limits or be clinically acceptable to the investigator for inclusion. Subjects could not consume alcohol from 48 h prior to the first dose of posaconazole until after the last pharmacokinetic blood sample was taken. Women of childbearing potential and male subjects agreed to use a medically accepted method of contraception while receiving study drugs and for 30 days after therapy. Women of childbearing potential were also required to have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at baseline (day Ϫ1) before dosing with the study drug. Subjects were excluded if they had any surgical or medical condition that could significantly alter the absorption, distribution, metabolism, or excretion of any drug; had a history of any infectious disease within 4 weeks prior to the first study drug administration; had a positive test result for hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus at screening; had a positive screen for drugs, with a high potential for abuse; had a history of alcohol or drug abuse within 2 years; had a history of mental instability or mood disorders; donated blood (1 pint [560 ml] or more) within 60 days; previously received posaconazole; had a history of allergy or intolerance to azole antifungal agents; received systemic azole antifungal therapy within 3 months; participated in another clinical study within 30 days; exhibited allergic reactions; or were staff (or family members of staff) at the study site. There were restrictions on concomitant medications, especially drugs known to lower the serum concentrations of, or to interact with, azole antifungals; drugs known to prolong heart ratecorrected QT intervals or cause torsade de pointes; or those known to be metabolized by the cytochrome P450 3A4 pathway.
Pharmacokinetic assessment. Blood samples for determination of plasma posaconazole were collected on each dosing day at predose (time zero); at 1, 2, 3, 4, 5, 6, 8, and 12 h postdose; and then at 24, 48, 72, 96, and 120 h postdose (i.e., up to 5 days postdose).
Plasma posaconazole was determined using liquid chromatography-tandem mass spectrometry (11) . The assay had a lower limit of quantitation of 5 ng/ml, a calibration range of 5 to 5,000 ng/ml, a precision (coefficient of variation) of 2.5% to 5%, and an accuracy (mean percent difference) of Ϫ0.4% to 2%. Pharmacokinetic data were analyzed using WinNonlin version 4.1 (Pharsight Corporation, Cary, NC).
The primary pharmacokinetic variables for bioavailability comparisons were the area under the concentration-time curve from time zero to the time of the final quantifiable sample (AUC tf ), the maximum observed plasma concentration (C max ), the time to C max (T max ), and the relative bioavailability. The terminalphase half-life was also assessed.
The C max and T max were reported as the observed values. The AUC was calculated from the concentration-time curve via the linear trapezoidal method. Derived log-transformed pharmacokinetic parameters (AUC tf and C max ) were statistically analyzed using a crossover analysis of variance model. The relative bioavailability was assessed by determining the 90% confidence interval (90% CI) of the ratio of two-treatment least-square means for the derived pharmacokinetic parameters. Posaconazole plus 8 oz Boost Plus was the main reference, and posaconazole alone was a secondary reference.
Safety assessment. The following safety variables were assessed: adverse events, clinical laboratory tests (hematology, clinical chemistry, and urinalysis), vital sign measurements (systolic and diastolic blood pressures, respiration rate, heart rate, and oral body temperature), physical examinations, and ECGs. Treatment-emergent adverse events (TEAEs) were summarized according to Medical Dictionary for Regulatory Activities version 10.1 preferred terms. Adverse events were graded by the investigator according to severity (mild, moderate, severe, or life-threatening) and relationship to the study medication (unlikely to be related, possibly related, or probably related).
RESULTS
Subjects.
Thirty healthy subjects (19 male and 11 female), ages 19 to 44 years, were randomized into the study. The demographic characteristics of the study subjects are shown in Table 3 . A total of 26 subjects completed the study; 2 subjects withdrew because of adverse events, and 2 subjects withdrew because of noncompliance.
Pharmacokinetic results. The pharmacokinetic parameters of posaconazole alone or with varying amounts of Boost Plus are summarized in Table 4 . The ratio estimates and 90% CIs of C max and AUC for posaconazole are presented in Table 5 .
The mean posaconazole concentration-time profiles alone and with varying amounts of nutritional supplement are presented in Fig. 1 . Following a single dose of 400 mg posaconazole oral suspension, posaconazole bioavailability increased almost linearly with increasing amounts of Boost Plus (Fig. 2) . Based on log-transformed data, the relative bioavailabilities (based on AUC) of posaconazole were 35% (fasting), 48% (1 oz Boost Plus), 60% (2 oz Boost Plus), and 77% (4 oz Boost Plus) of the level reached in the presence of 8 oz Boost Plus. Compared with the levels reached under fasting conditions, posaconazole AUC and C max values increased 2.9-and 3.5-fold, respectively, when given with 8 oz Boost Plus. Although the extent of absorption increased with coadministration with Boost Plus, the T max was not affected (the median T max was observed at 5 h across all treatment groups). The variability of posaconazole exposure in plasma, in terms of AUC tf , ranged from 38% to 68%, with lower variabilities appearing to be associated with larger amounts of Boost Plus. Safety and tolerability. Overall, the five treatment regimens were comparable in terms of safety and tolerability (Table 6 ). Most TEAEs were mild or moderate in severity. Two subjects reported severe TEAEs (stomach discomfort and nasal congestion) following administration of posaconazole plus 1 oz Boost Plus; neither event led to study drug discontinuation or was considered by the investigator to be related to treatment.
All treatment-related adverse events (TRAEs) were mild to moderate in severity. The only TRAEs reported by more than one subject were headache (n ϭ 4) and pharyngolaryngeal pain (n ϭ 3). The only TRAE other than headache and pharyngolaryngeal pain of moderate severity was dysuria (n ϭ 1), in a subject receiving posaconazole plus 4 oz Boost Plus; the event resolved spontaneously the same day. Two subjects discontinued because of elevated liver function test results, which were reported as adverse events; one was considered possibly related to study treatment, and one was considered unlikely to be related. No clinically significant abnormalities in any other laboratory assessment or in any of the ECG or vital sign parameters were reported.
DISCUSSION
The effects of food on the bioavailability of azole antifungals vary among agents. Food does not have a clinically significant effect on the absorption of fluconazole (4) but significantly decreases voriconazole absorption (8) . When the drug is administered with a meal, absorption of the capsule formulation of itraconazole is increased (1, 15) , whereas absorption of the oral solution of itraconazole is decreased (13) , relative to the level of absorption during a fasting state. The presence of food may enhance the solubility of itraconazole capsules and posaconazole oral suspension because of their lipophilic nature and resulting poor solubility in water (1, 5) .
Results from the current study demonstrated that following a single 400-mg dose of posaconazole oral suspension, the bioavailability of posaconazole increased almost linearly with increasing amounts of Boost Plus (up to 8 oz) in healthy subjects. Compared with the levels reached under fasting conditions, posaconazole AUC and C max values increased 2.9-and 3.5-fold, respectively, when the drug was given with 8 oz Boost Plus. These findings were in agreement with results from a previous study, which reported that posaconazole AUC and C max values increased ϳ2.6-and ϳ3.4-fold, respectively, after administration of 8 oz Boost Plus compared with the levels reached under fasting conditions (10) .
A previous study of the effect of food on posaconazole bioavailability in healthy adults reported that the mean C max and AUC values were approximately 4-fold greater when posaconazole was administered with a high-fat meal and 3-and 2.6-fold greater, respectively, when the drug was administered with a nonfat meal than when administered under fasting conditions (3) . The results of this study, combined with the previous nutritional supplement bioavailability study (10) , indicate that the administration of posaconazole with 8 oz Boost Plus enhances bioavailability to an extent similar to that achieved by administration with a nonfat meal.
In conclusion, the data presented in this study suggest that the concomitant administration of posaconazole with a liquid nutritional supplement could enhance posaconazole bioavailability in patients at risk from IFI who are unable to eat or tolerate a full meal. 
